Soligenix Reports Q3 2025 Financial Results and Clinical Progress Across Rare Disease Pipeline

Soligenix Inc. reported third quarter 2025 financial results while highlighting significant clinical progress across its rare disease pipeline. The company confirmed upcoming milestones including top-line Phase 2a results for SGX302 in psoriasis and provided an enrollment update for its confirmatory Phase 3 HyBryte study in cutaneous T-cell lymphoma. CEO Christopher J. Schaber announced that the first Data Monitoring Committee review found no safety concerns for HyBryte, maintaining a consistent safety profile across clinical trials.

The company's financial position remains stable with $10.5 million in cash as of September 30, 2025, providing an operating runway expected to extend through 2026. This financial stability allows Soligenix to continue evaluating strategic options to advance its late-stage pipeline while maintaining progress across multiple clinical programs. The company's Specialized BioTherapeutics business segment continues development of HyBryte as a novel photodynamic therapy utilizing safe visible light for cutaneous T-cell lymphoma treatment.

Beyond the immediate clinical programs, Soligenix maintains an expanding pipeline including development of synthetic hypericin for psoriasis treatment and its first-in-class innate defense regulator technology. The dusquetide program targets inflammatory diseases including oral mucositis in head and neck cancer patients, while SGX945 addresses Behcet's Disease. These programs represent significant opportunities in rare disease markets with substantial unmet medical needs.

The Public Health Solutions business segment continues advancing vaccine candidates including RiVax for ricin toxin protection and programs targeting filoviruses such as Marburg and Ebola. The CiVax COVID-19 vaccine candidate incorporates the company's proprietary ThermoVax heat stabilization platform technology. This business segment has been supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. Additional information about the company's developments is available through their newsroom at https://ibn.fm/SNGX.

With multiple clinical milestones approaching and a diversified pipeline addressing both rare diseases and public health threats, Soligenix demonstrates continued progress toward potential commercialization of novel therapies. The combination of clinical advancement and financial stability positions the company for significant regulatory and commercial opportunities in the coming years across its specialized therapeutic areas.